D-Attachment-SOW Protein analysis in cerebrospinal fluid samples (CSF).pdf
PDF 932 KB Posted
- Attached to
- Protein Analysis in Cerebrospinal Fluid Samples (CSF) Federal contract opportunity
- Solicitation number
- 75N95024Q00278
About this file
This document is a Statement of Work (SOW) for a federal contract opportunity to perform protein analysis on cerebrospinal fluid (CSF) samples. The objective is to detect the presence or absence of misfolded alpha-synuclein (ASyn) protein in CSF samples from patients with Alzheimer's Disease and Related Dementias (ADRD) using a new commercial assay. The anticipated period of performance is from August 2024 through September 2028, with a base period and 24 optional periods. The government will provide 6,150 CSF samples to the contractor, who will use the SYNTap Biomarker Test to analyze the samples and provide raw data in Excel format. The contractor must comply with Section 508 accessibility requirements. The associated federal contract opportunity is Solicitation Number 75N95024Q00278 for "Protein Analysis in Cerebrospinal Fluid Samples (CSF)," issued by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse. The solicitation is a request for quotation without set-aside restrictions, with a NAICS code of 621511 and a $41.5 million small business size standard. Award will be made on a best value basis considering technical capability, past performance, and price.
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| D-Attachment-Invoicing Instructions.pdf | ||
| D-Attachment-SBCX Industry Subcontracting Guide.pdf | ||
| D-Attachment-FAR 52.212-5 (May 2024).pdf | ||
| D-Attachment-FAR 52.212-4 Addendum.pdf | ||
| D-Attachment-FAR_52.204-26 (Oct 2020).pdf | ||
| D-Attachment-FAR_52.204-24 (Nov 2021).pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Version 11-30-2016-1 FAR Part 11—Describing Agency Needs
Statement of Work (SERVICES) SOW
GENERAL INFORMATION
Title of Project:
Protein analysis in cerebrospinal fluid samples (CSF)
Statement of Need and Purpose:
Center for Alzheimer’s Disease and Related Dementias (CARD) is endevoring on a large-scale phenotyping project to characterize patient samples afflicted with Alzheimer’s Disease and Related Dementias (ADRD). To date, alpha synuclein is traditionally difficult to analyze in CSF.
Recently, a new method has been developed to identify misfolded ASyn seeds. Identifying misfolded ASyn protein in CSF will advance our understanding of ADRD.
Background Information and Objective:
Lewy body pathology is one of the co-occurring non-AD pathologies that can contribute to overall clinical and cognitive deterioration, even in cases of dominantly inherited AD. The advent of molecular imaging and fluid-based biomarkers allowed for detection of AD neuropathological changes in living individuals. However, until recently biomarkers have remained mostly unavailable for non-AD neuropathological changes, including Lewy body disease. Without incorporation of biomarkers to recognize the presence and severity of comorbid Lewy body pathology, every clinical trial designed to show the effectiveness of an AD treatment will continue to systematically underestimate the maximum therapeutic effect of the drug. Alpha-synuclein (ASyn) has been identified as a hallmark protein involved in synucleinopathies but accurate detection of pathogenic ASyn has hindered advancements in this area of research. However, recent studies by Soto and colleagues led to the development of a commercial assay (Amprion SYNTap®) for detection of aggregates of misfolded ASyn seeds in CSF. We aim to detect the presence or absence of ASyn seeds by using Amprion SYNTap assay.
Anticipated Period of Performance:
Base Period: August 1, 2024 thru October 31, 2024 (QTY of Samples = 1,200) Optional Period 1: November 1, 2024 thru December 31, 2024 (QTY of samples = 200) Optional Period 2: January 1, 2025 thru February 28, 2025 (QTY of samples = 200) Optional Period 3: March 1, 2025 thru April 30, 2025 (QTY of samples = 200) Optional Period 4: May 1, 2025 thru June 30, 2025 (QTY of samples = 200) Optional Period 5: July 1, 2025 thru August 31, 2025 (QTY of samples = 200) Optional Period 6: September 1, 2025 thru October 31, 2025 (QTY of samples = 200) Optional Period 7: November 1, 2025 thru December 31, 2025 (QTY of samples = 200) Optional Period 8: January 1, 2026 thru February 28, 2026 (QTY of samples = 200)
Optional Period 9: March 1, 2026 thru April 30, 2026 (QTY of samples = 200) Optional Period 10: May 1, 2026 thru June 30, 2026 (QTY of samples = 200) Optional Period 11: July 1, 2026 thru August 31, 2026 (QTY of samples = 200) Optional Period 12: September 1, 2026 thru October 31, 2026 (QTY of samples = 200) Optional Period 13: November 1, 2026 thru December 31, 2026 (QTY of samples = 200) Optional Period 14: January 1, 2027 thru February 28, 2027 (QTY of samples = 200) Optional Period 15: March 1, 2027 thru April 30, 2027 (QTY of samples = 200) Optional Period 16: May 1, 2027 thru June 30, 2027 (QTY of samples = 200) Optional Period 17: July 1, 2027 thru August 31, 2027 (QTY of samples = 200) Optional Period 18: September 1, 2027 thru October 31, 2027 (QTY of samples = 200) Optional Period 19: November 1, 2021 thru December 31, 2027 (QTY of samples = 200) Optional Period 20: January 1, 2028 thru February 28, 2028 (QTY of samples = 200) Optional Period 21: March 1, 2028 thru April 30, 2028 (QTY of samples = 200) Optional Period 22: May 1, 2028 thru June 30, 2028 (QTY of samples = 200) Optional Period 23: July 1, 2028 thru August 31, 2028 (QTY of samples = 200) Optional Period 24: September 1, 2028 thru September 30, 2028 (QTY of samples = 200)
SCOPE OF WORK
General Requirements:
Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work below.
Specific Requirements:
Contractor shall use SYNTap Biomarker Test using a Seed Amplification Assay (SAA) to determine the absence or presence of alpha synuclein in samples of CSF.
Unused Government samples shall be securely stored at -80 and shipped back to Government at completion of the project.
LEVEL OF EFFORT
Vendor staff will provide the assay results via reporting transfer thru email.
GOVERNMENT RESPONSIBILITIES
Government will provide 6,150 CSF samples to contractor. Samples will be provided at 500ul volume per sample.
DELIVERY OR DELIVERABLES
Raw data in Excel format delivered by Google Cloud server
REPORTING REQUIREMENTS
The Contractor shall submit the following reports as specified below. All reports shall be submitted electronically either as a Word document or PDF file or Excel file, as appropriate.
Weekly reports through email related to receival of samples, experimental progress, experimental results, and sample failure, and sample storage.
OTHER CONSIDERATIONS
Travel:
The principal place of performance is the Contractor’s work site. Travel for contractor employees will not be necessary.
Key Personnel:
Contractor will provide a dedicated project manager to the government as a contact point for the services.
Information System Security Plan:
Not Applicable
Data Rights:
The Contractor will be responsible for the transfer of de-identified raw data to the Government.
Data shall be transmitted electronically. The Contractor shall provide consultation on related features of manuscript preparation.
Section 508—Electronic and Information Technology Standards:
The contractor shall comply with Section 508 of the Rehabilitation Act (29 U.S.C. § 794d), as amended by the Workforce Investment Act of 1998 (P.L. 105-220), August 7, 1998.
Publications and Publicity:
Not Applicable
Confidentiality of Information:
Not Applicable
File details come from the government source that posted it. Updated .